Archive | 2018 Rayno Biopharmaceuticals Portfolio

The Rayno Biopharmaceuticals Portfolio up to date picks for 2017 are below.  We have recovered from the bear market for biotechnology stocks since the 2015 “bubble” peak of July 17, 2015. The sector bottomed on November 3, 2016 with IBB at  $246 and is up 19% YTD.

Rayno Life Science Portfolio 2017

Update-1 6/27/17 With the XBI up 34% YTD at $79.34, take a little off for future trades. ===== Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up 20.9%, our top pick for aggressive […]

Continue Reading 0

Biotechs Running Again: Rayno Life Science Stocks-See Picks…Earnings Updates

Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for EPS was confirmed at $5.44-5.54. Stock closed up 1.55% today to $66.05. Alexion […]

Continue Reading 0

Vertex (VRTX) Soars on Clinical Data and Boosts Biotech Stocks…Updates

Update…3/31/17 Performance %: March and YTD FBT  -0.83, +15.87 FBIOX  -2.43, +15.79  * Fidelity ahead of IBB in 2017 IBB   -3.05,+10.5 QQQ +1.04, +11.73 XBI   -2.82, +17.15 XLV   -1.9, +7.86 Notable Rayno Portfolio Picks %: March and YTD ABBV  +2.9,  +4.08 AMGN  -8.95, +12.22 BLUE  +7,  +47.33 FMI +13.85  +82.2 HOLX  +3.18, […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

Trump Biotech Rally: After Comey Sell-Off and Since Election

  Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is because the end of the grueling election has removed […]

Continue Reading 0

Rayno 2016 Life Science Portfolio Update…BLUE,IBB…Update-2

Update-1… See Caution 9/29 Update-2…See Rayno Biobeat for updates after Trump Rally. For overweighting biotechs in a portfolio consider XBI instead of IBB to get mid and small cap exposure. ——– Rayno Portfolio Outperforms the Market Biotech stocks are near their intermediate highs but still down in 2016 : IBB at $295 down 12.78% and […]

Continue Reading 0

FED Fear Factor Fades then Biotechs Rally: AMGN,IBB…Update-1 Bearish Reversal

Update-1… 9/13… Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks and significantly a major move up in the Ten Year Treasury Yield […]

Continue Reading 0

Biotechs Get a Turbo Boost from Biogen(BIIB)…Update-1 GILD

Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by $1B to the $29,5B-$31.5B range. Pricing pressures continued on Hep-C drugs and new […]

Continue Reading 0

Biotech Rally Up 8% from Brexit Bottom: Rayno Biopharmaceutical Portfolio Update: July 11, 2016…Update-1

Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still rallying off last Friday’s job report and Alcoa (AA) earnings yesterday. […]

Continue Reading 0

Foundation Medicine (FMI): New Pick Added To Raygent Core Portfolio

Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists […]

Continue Reading 0